Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
暂无分享,去创建一个
E. Polo | M. Guillot | M. Valladares-Ayerbes | F. Rivera | R. López | E. Díaz-Rubio | E. Aranda | E. Asensio-Martínez | M. Safont | J. Sastre | P. García-Alfonso | J. Viéitez | A. La Casta | S. Gil | M. T. Cano | B. García-Paredes | G. Quintero | L. Robles-Díaz | J. J. Reina-Zoilo | A. Salud-Salvia
[1] F. Rivera,et al. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial , 2020, ESMO Open.
[2] Donna Niedzwiecki,et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Meyerhardt,et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial , 2017, JAMA.
[4] Sabine Tejpar,et al. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression , 2016, Clinical Cancer Research.
[5] E. S. Kopetz,et al. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. , 2015, Journal of gastrointestinal oncology.
[6] M. Wiese,et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer , 2015, British Journal of Cancer.
[7] Claudia Maggi,et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. , 2015, European journal of cancer.
[8] Hartmut Link,et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[9] J. Hecht,et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[11] J. Tabernero,et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. , 2012, The oncologist.
[12] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[13] I. Nagtegaal,et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Michael Morse,et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.